Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

2649 - Cabozantinib in patients with advanced penile squamous cell carcinoma (PSCC): the open-label, single-arm, single-center, phase 2, CaboPen trial


10 Sep 2017


Poster display session


Cytotoxic Therapy;  Penile Cancer


Andrea Necchi


Annals of Oncology (2017) 28 (suppl_5): v295-v329. 10.1093/annonc/mdx371


A. Necchi1, L. Mariani2, M. Colecchia3, P. Giannatempo1, D. Raggi1, G. Calareso4, N. Nicolai5, M. Catanzaro5, T. Torelli5, F. Perrone6, R. Salvioni5

Author affiliations

  • 1 Medical Oncology, Fondazione IRCCS - Istituto Nazionale dei Tumori, 20133 - Milan/IT
  • 2 Clinical Epidemiologi And Trials Organization Unit, Fondazione IRCCS - Istituto Nazionale dei Tumori, 20133 - Milan/IT
  • 3 Pathology, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milano/IT
  • 4 Radiology, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milano/IT
  • 5 Urology, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milano/IT
  • 6 Molecular Pathology, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milano/IT


Abstract 2649


Chemotherapy (ChT) exerts moderate activity in advanced and metastatic PSCC, and efficacy outcomes are poor. Neoadjuvant treatment is a reliable setting to address activity of new drug approach (Necchi A et al. ASCO-GU 2017). The vascular endothelial growth factor (VEGF) receptor is overexpressed in approximately 50% of PSCC. Cabozantinib (Cabo) is a multiple receptor tyrosine kinase inhibitor (TKI) primarily targeting MET and VEGFR2.

Trial design

In an open-label, single-arm, single-center, phase 2 trial, patients (pts) with clinical stage N2-3 (TNM 2009, locally-advanced [LA]) or M1 PSCC will receive Cabo, orally, at a dose of 60 mg/day continuously until surgery, evidence of disease progression or onset of unacceptable toxicity. Prior ChT administration is not allowed. Response will be evaluated by RECIST criteria v.1.1, matched with 18FDG-PET/CT assessment, every 2 months. At each time of disease restaging, responding pts with LA PSCC who will be considered eligible to radical lymphadenectomy will undergo surgery. After surgery, pts will be managed according to standard guidelines. The primary endpoint (EP) is the objective response-rate (ORR=CR+PR according to RECIST v1.1). Secondary EP are safety, progression-free survival (PFS) and overall survival (OS), and pathologic response. The study is planned according to Simon’s Optimal two-stage design, with H1=20% and H0= 5%, and type I and type II error rates set at the 10% level. In stage 1, 12 evaluable pts will be accrued. If 1 pt at least will be responding, enrolment will be extended to the 2nd stage for further 25 pts. If, out of the total of 37 pts, 4 at least will be responding, treatment will be declared worthy for further investigations. Stopping rules based on the Bayesian posterior probability (PP) to demonstrate that the ORR exceeded 20% are set. Translational analyses on pre- and post-Cabo tumor samples and matched blood samples will include in-situ hybridization for HPV and next generation sequencing (Ion Torrent Personal Genome Machine). These profiles will be associated with response to treatment and PFS/OS (EudraCT number 2017-001963-19).

Clinical trial identification

EudraCT number 2017-001963-19

Legal entity responsible for the study

Fondazione IRCCS Istituto Nazionale dei Tumori




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.